Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rosing

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding studyC van Kesteren, E Cvitkovic, A Taamma, et al.
British Journal of Cancer|May 20, 2004
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeksT Kerbusch, G Groenewegen, R A A Mathôt, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2020
Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapyW J Koemans, R T van der Kaaij, E C E Wassenaar, et al.
Investigational New Drugs|September 13, 2015
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancerR van der Noll, W M Smit, A N M Wymenga, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2005
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancerA M E Bos, F Y F L De Vos, E G E de Vries, et al.
British Journal of Cancer|September 19, 2002
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecinN E Schoemaker, C van Kesteren, H Rosing, et al.
Gynecologic Oncology|June 8, 2002
Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancerL S Hofstra, A M E Bos, E G E de Vries, et al.
Cancer Chemotherapy and Pharmacology|March 22, 2023
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patientsStefanie L Groenland, J M Janssen, C M Nijenhuis, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 14, 2009
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumorsR L Oostendorp, J Loftiss, S Goel, et al.
Cancer Chemotherapy and Pharmacology|February 14, 2015
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapyM Joerger, A D R Huitema, H Boot, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding studyC van Kesteren, E Cvitkovic, A Taamma, et al.
British Journal of Cancer|May 20, 2004
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeksT Kerbusch, G Groenewegen, R A A Mathôt, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 18, 2020
Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapyW J Koemans, R T van der Kaaij, E C E Wassenaar, et al.
Investigational New Drugs|September 13, 2015
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancerR van der Noll, W M Smit, A N M Wymenga, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2005
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancerA M E Bos, F Y F L De Vos, E G E de Vries, et al.
British Journal of Cancer|September 19, 2002
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecinN E Schoemaker, C van Kesteren, H Rosing, et al.
Gynecologic Oncology|June 8, 2002
Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancerL S Hofstra, A M E Bos, E G E de Vries, et al.
Cancer Chemotherapy and Pharmacology|March 22, 2023
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patientsStefanie L Groenland, J M Janssen, C M Nijenhuis, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 14, 2009
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumorsR L Oostendorp, J Loftiss, S Goel, et al.
Cancer Chemotherapy and Pharmacology|February 14, 2015
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapyM Joerger, A D R Huitema, H Boot, et al.
Pageof 18